S930 Safety of Ustekinumab Across Approved Adult Indications: Pooled Safety Analysis in Crohn’s Disease, Ulcerative Colitis, Psoriasis, and Psoriatic Arthritis Through up to 5 Years

Introduction: Ustekinumab (UST) is a well-established therapy and was approved for treatment of adults with psoriasis (PsO) in 2009, psoriatic arthritis (PsA) in 2013, Crohn’s disease (CD) in 2016, and ulcerative colitis (UC) in 2019. An integrated analysis of safety data through 1 year1 and the more recently presented 2020 IBD Pooled Safety Dataset showed a favorable safety profile for UST across indications that was generally similar to placebo (PBO). Here, we present an integrated analysis of the pooled safety data incorporating phase 2/3 long-term safety data from IBD studies through up to 5 years in CD and 2 years in UC and psoriatic disease studies through up to 5 years in PsO and 1 year in PsA. Methods: Data from 13 phase 2/3 studies in approved indications were pooled. Concomitant immunomodulators and corticosteroids were permitted for IBD and PsA pts, but not PsO pts. All pts who received ≥1 dose of UST were included in this analysis. Safety outcomes are presented as events per 100 patient-years (PY) of follow-up and 95% confidence interval (CIs). Of note, the PBO-controlled period in most PsO studies was 12 wks, and 16 wks in PSA. Results: Across all indications, 2501 pts were treated with PBO with 1244 PYs of follow-up and 6710 pts were treated with UST with 13807 PYs of follow-up. Rates of key events per 100 PYs and corresponding 95% CIs were generally similar between UST and PBO groups (Table 1). In pooled indications in the PBO and UST groups, respectively, the most frequent adverse events (AEs; excluding preferred terms of CD and UC) were nasopharyngitis (20.83 vs 20.87), upper respiratory tract infection (13.51 vs 14.53), arthralgia (13.99 vs 7.01), abdominal pain (10.77 vs 4.01), and diarrhea (6.67 vs 3.88). Anal abscess (PBO 0.72 vs UST 0.17), pneumonia (PBO 0.32 vs UST 0.14), and cellulitis (PBO 0.16 vs UST 0.11) were the most frequently reported serious infections. Events of malignancy and death were less frequently reported, particularly in the PBO group and as such, CIs were wide. Conclusion: The safety profile of UST across pooled indications was favorable through up to 5 yrs, confirming the well-established safety profile of UST in psoriatic and IBD indications.Table 1.: Key Safety Events in CD, UC, PsO, and PsA Studies Through Up to 5 Years

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.